Mitomycin-C Use and Complications in Ophthalmology
International Journal of Clinical and Experimental Ophthalmology · 2017
DOI: 10.29328/journal.hceo.1001004 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical and Experimental Ophthalmology, 2017. Verfasst von Tongabay Cumurcu. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mitomycin-C, irst found its way into ophthalmic use in 1969, in Japan, where recurrent pterygia were successfully treated with the drug which is an antineoplastic / antibiotic agent isolated from the soil bacterium Streptomyces caespitosus [1]. It is an anti-metabolite with anti-proliferative effect on cells showing the highest rate of mitosis by inhibiting DNA synthesis and interferes with RNA transcription and protein synthesis [2].
Zitieren
APA
Cumurcu, T. (2017). Mitomycin-C Use and Complications in Ophthalmology. International Journal of Clinical and Experimental Ophthalmology. https://doi.org/10.29328/journal.hceo.1001004
Vancouver
Cumurcu T. Mitomycin-C Use and Complications in Ophthalmology. International Journal of Clinical and Experimental Ophthalmology. 2017. doi:10.29328/journal.hceo.1001004
BibTeX
@article{Cumurcu2017,
author = {Cumurcu, Tongabay},
title = {Mitomycin-C Use and Complications in Ophthalmology},
journal = {International Journal of Clinical and Experimental Ophthalmology},
year = {2017},
doi = {10.29328/journal.hceo.1001004}
}
EUVIMED